BR112015000685A2 - método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. - Google Patents
método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza.Info
- Publication number
- BR112015000685A2 BR112015000685A2 BR112015000685A BR112015000685A BR112015000685A2 BR 112015000685 A2 BR112015000685 A2 BR 112015000685A2 BR 112015000685 A BR112015000685 A BR 112015000685A BR 112015000685 A BR112015000685 A BR 112015000685A BR 112015000685 A2 BR112015000685 A2 BR 112015000685A2
- Authority
- BR
- Brazil
- Prior art keywords
- influenza
- identifying
- patient
- suspected
- assessing
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title 3
- 206010035737 Pneumonia viral Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
- 208000009421 viral pneumonia Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902954A AU2012902954A0 (en) | 2012-07-10 | Risk stratification in influenza | |
| PCT/AU2013/000765 WO2014008545A1 (en) | 2012-07-10 | 2013-07-10 | Risk stratification in influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015000685A2 true BR112015000685A2 (pt) | 2017-11-28 |
Family
ID=49915252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015000685A BR112015000685A2 (pt) | 2012-07-10 | 2013-07-10 | método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10036075B2 (https=) |
| EP (1) | EP2872891B1 (https=) |
| JP (1) | JP6097388B2 (https=) |
| KR (1) | KR20150040289A (https=) |
| CN (1) | CN104769430B (https=) |
| AU (1) | AU2013289854B2 (https=) |
| BR (1) | BR112015000685A2 (https=) |
| CA (1) | CA2877400A1 (https=) |
| DK (1) | DK2872891T3 (https=) |
| WO (1) | WO2014008545A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3367099B1 (en) | 2012-02-09 | 2021-05-26 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| WO2015103664A1 (en) * | 2014-01-09 | 2015-07-16 | Nepean Blue Montains Local Health District | Risk stratification in influenza |
| BR112017002884A2 (pt) | 2014-08-14 | 2018-01-30 | Memed Diagnostics Ltd | ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano? |
| CN111624345A (zh) | 2014-12-11 | 2020-09-04 | 米密德诊断学有限公司 | 用于诊断多种感染的标记组合及其使用方法 |
| EP3146974A1 (en) | 2015-09-25 | 2017-03-29 | Universite Claude Bernard - Lyon 1 | Biomarkers for early determination of severity of influenza related disease |
| EP3423590A4 (en) | 2016-03-03 | 2020-02-26 | Memed Diagnostics Ltd. | DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS |
| IL287757B (en) | 2016-03-03 | 2022-07-01 | Memed Diagnostics Ltd | Analyzing rna for diagnosing infection type |
| EP3482201B1 (en) | 2016-07-10 | 2022-12-14 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| EP3482200B1 (en) | 2016-07-10 | 2022-05-04 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| US12344893B2 (en) | 2018-06-05 | 2025-07-01 | Washington University | Nasal genes used to identify, characterize, and diagnose viral respiratory infections |
| JP7846017B2 (ja) * | 2020-04-09 | 2026-04-14 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 気道感染症の診断のためのバイオマーカー |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792626A (en) * | 1996-09-18 | 1998-08-11 | Incyte Pharmaceuticals, Inc. | Human interferon-inducible protein |
| US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
| US7214498B2 (en) * | 2001-03-23 | 2007-05-08 | Benaroya Research Institute At Virginia Mason | Tumor associated antigens and methods of using the same |
| JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
| WO2005068664A2 (en) * | 2004-01-09 | 2005-07-28 | The Regents Of The University Of California | Cell-type-specific patterns of gene expression |
| US20050244851A1 (en) * | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| WO2007034280A2 (en) * | 2005-09-19 | 2007-03-29 | Moshe Amihood Blay | Composition and method for prevention of influenza |
| AU2007286915B2 (en) * | 2006-08-11 | 2014-05-15 | Baylor Research Institute | Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections |
| WO2009148150A1 (ja) * | 2008-06-06 | 2009-12-10 | 国立大学法人富山大学 | インフルエンザウィルス検出用デバイス |
| WO2010076788A2 (en) * | 2008-12-29 | 2010-07-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
| WO2011008349A2 (en) * | 2009-05-26 | 2011-01-20 | Duke University | Methods of identifying infectious disease and assays for identifying infectious disease |
| EP2451476A4 (en) | 2009-07-06 | 2013-07-03 | Alnylam Pharmaceuticals Inc | BIOTRAITEMENT BASED ON CELLS |
| US20120214705A1 (en) * | 2009-09-28 | 2012-08-23 | The Regents Of The University Of California Office of Technology, | Beta-defensin 2 genetic variation predicts h. pylori susceptibility |
| EP2751286A1 (en) * | 2011-09-04 | 2014-07-09 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Prognostic methods and compositions for predicting interferon treatment eficacy in a subject |
-
2013
- 2013-07-10 DK DK13817599.7T patent/DK2872891T3/da active
- 2013-07-10 CA CA2877400A patent/CA2877400A1/en not_active Abandoned
- 2013-07-10 BR BR112015000685A patent/BR112015000685A2/pt not_active Application Discontinuation
- 2013-07-10 US US14/410,367 patent/US10036075B2/en active Active
- 2013-07-10 JP JP2015520775A patent/JP6097388B2/ja not_active Expired - Fee Related
- 2013-07-10 EP EP13817599.7A patent/EP2872891B1/en active Active
- 2013-07-10 KR KR20157003223A patent/KR20150040289A/ko not_active Withdrawn
- 2013-07-10 AU AU2013289854A patent/AU2013289854B2/en not_active Ceased
- 2013-07-10 CN CN201380046905.6A patent/CN104769430B/zh active Active
- 2013-07-10 WO PCT/AU2013/000765 patent/WO2014008545A1/en not_active Ceased
-
2018
- 2018-06-25 US US16/017,197 patent/US20180298455A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150040289A (ko) | 2015-04-14 |
| EP2872891A1 (en) | 2015-05-20 |
| CA2877400A1 (en) | 2014-01-16 |
| US20150322538A1 (en) | 2015-11-12 |
| WO2014008545A1 (en) | 2014-01-16 |
| CN104769430A (zh) | 2015-07-08 |
| EP2872891A4 (en) | 2016-01-20 |
| CN104769430B (zh) | 2018-12-14 |
| JP6097388B2 (ja) | 2017-03-15 |
| AU2013289854B2 (en) | 2016-03-24 |
| US10036075B2 (en) | 2018-07-31 |
| JP2015530868A (ja) | 2015-10-29 |
| AU2013289854A2 (en) | 2015-02-26 |
| DK2872891T3 (da) | 2019-05-13 |
| AU2013289854A1 (en) | 2015-01-22 |
| EP2872891B1 (en) | 2019-03-13 |
| US20180298455A1 (en) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015000685A2 (pt) | método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015009636A8 (pt) | composto, métodos para o tratamento de um hospedeiro infectado, métodos para a prevenção de uma infecção, métodos para a redução da atividade biológica de uma infecção e uso de um composto | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| EP2839037A4 (en) | BIOMARKERS FOR IDENTIFYING TREATMENT-RESPONSIBLE PATIENTS AND TREATMENT OF SUCH PATIENTS | |
| MX360056B (es) | Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. | |
| BR112013024574A2 (pt) | polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo | |
| BR112015002524A2 (pt) | derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças. | |
| HUE053946T2 (hu) | 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére | |
| BR112013020352A2 (pt) | composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo | |
| EP2968525A4 (en) | MORBUS NEWCASTLE VIRUSES AND USES THEREOF | |
| CU23938B1 (es) | Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2 | |
| BR112019009256A2 (pt) | métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo | |
| EP2493479A4 (en) | METHOD FOR THE TREATMENT OF VIRUS DISEASES | |
| BR112015007758A2 (pt) | dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho. | |
| MX350282B (es) | Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas. | |
| BR112015017241A2 (pt) | doadores de nitroxil com índice terapêutico melhorado | |
| BR112012002001A2 (pt) | método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit | |
| BR112016028446A2 (pt) | inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5 | |
| BR112014020885A2 (pt) | oligonucleotídeos para modulação da expressão gênica e seu uso | |
| BR112013017148A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou distúrbio, método para tratar uma doença mediada por hdac e método para tratar tanto as doenças associadas com hedgehog como as doenças associadas à hdac | |
| BR112013029514A2 (pt) | composição imunogênica, vacina, e, método de tratar ou impedir uma doença |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |